Innovative Therapies for Orphan Diseases
Kelvin Therapeutics is a preclinical stage biotechnology company focused on developing innovative therapies for rare and under-served diseases with significant unmet medical need.
The company combines deep scientific expertise, translational biology, and advanced preclinical research to identify novel therapeutic opportunities where current treatment options remain limited or ineffective. Its mission is to bring new hope to patients suffering from debilitating conditions that have historically received insufficient investment and attention including Duchenne Muscular Dystrophy.
Led by a team of experienced biotech entrepreneurs, academic scientists, clinicians, and regulatory experts.
The Kelvin Therapeutics team have extensive experience discovering, developing, and advancing novel therapeutics into the clinic, including multiple assets that have reached human clinical trials, major pharmaceutical partnerships, and successful commercial exits.